Skip to main content

Table 5 Longitudinal change of comprehensive MRI measurements and clinical outcomes for three dose groups during the trial

From: Multi-compositional MRI evaluation of repair cartilage in knee osteoarthritis with treatment of allogeneic human adipose-derived mesenchymal progenitor cells

Measurement Group Base time 48 weeks P value
T1rho (ms) High 41.55 ± 2.86 38.82 ± 2.11 0.002*
Mid 39.30 ± 2.01 37.48 ± 1.93 0.002*
Low 38.91 ± 3.24 37.94 ± 3.13 0.038*
T2 (ms) High 42.12 ± 4.13 39.65 ± 3.37 0.003*
Mid 40.16 ± 2.60 37.21 ± 1.73 0.003*
Low 43.77 ± 6.09 39.73 ± 2.78 0.075
T2star (ms) High 23.43 ± 2.30 21.77 ± 1.41 0.011*
Mid 24.22 ± 2.18 22.60 ± 1.77 0.012*
Low 25.11 ± 2.32 23.09 ± 1.27 0.012*
R2star (s−1) High 48.47 ± 4.69 51.25 ± 2.85 0.021*
Mid 44.57 ± 8.26 46.80 ± 10.57 0.180
Low 45.21 ± 3.16 48.57 ± 2.29 0.005*
ADC (×10−3 mm2/s) High 1.53 ± 0.10 1.37 ± 0.08 0.026*
Mid 1.59 ± 0.15 1.52 ± 0.11 0.112
Low 1.56 ± 0.12 1.42 ± 0.14 0.052
FA High 0.47 ± 0.04 0.51 ± 0.05 0.05
Mid 0.45 ± 0.06 0.47 ± 0.04 0.225
Low 0.47 ± 0.02 0.51 ± 0.03 0.075
WORMS High 10.88 ± 5.45 11.04 ± 5.02 0.918
Mid 12.42 ± 7.16 12.38 ± 7.17 0.985
Low 14.43 ± 7.06 15.10 ± 6.90 0.758
CV High 27,863.12 ± 5688.74 28,073.37 ± 5871.8 0.599
Mid 34,645.82 ± 4666.97 34,870.24 ± 4991.32 0.758
Low 31,815.91 ± 4879.96 31,607.52 ± 5238.41 0.514
WOMAC High 38.83 ± 12.61 24.33 ± 12.88 0.077
Mid 48.83 ± 16.22 23.17 ± 12.89 0.035*
Low 46.17 ± 21.48 27.50 ± 18.64 0.139
SF-36 High 88.83 ± 14.41 74.0 ± 15.74 0.119
Mid 89.67 ± 10.21 70.5 ± 8.41 0.005*
Low 91.0 ± 13.80 71.5 ± 14.88 0.040*
  1. Values are given as mean ± standard deviation of the mean
  2. *Significantly different between two groups (P < 0.05)